Viridian Therapeutics
Logotype for Viridian Therapeutics Inc

Viridian Therapeutics (VRDN) investor relations material

Viridian Therapeutics Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Viridian Therapeutics Inc
Q3 2026 earnings summary4 Nov, 2026

Executive summary

  • Lumvoa generated $24.7M in Q3 2026 net product revenue, its first launch quarter; more than 100 patients had started therapy by September 30.

  • Q3 net loss was $101.2M, compared with $34.6M a year earlier; cash, cash equivalents and marketable securities totaled $955.2M at quarter-end.

  • Pipeline priorities include elegrobart, VRDN-008 and VRDN-292, with milestones expected through Q4 2026 and Q1 2027.

Financial highlights

  • Q3 total revenue was $25.8M versus $70.6M a year earlier; the prior-year period included a one-time $70.0M Kissei upfront license payment.

  • Q3 operating expenses were $129.2M, including $70.1M R&D and $57.6M SG&A; operating loss was $103.5M.

  • Q3 net loss was $101.2M versus $34.6M; 9M net loss was $333.2M versus $222.2M.

  • 9M revenue was $26.2M versus $70.7M; 9M R&D was $219.3M versus $249.7M, while SG&A was $151.3M versus $61.6M.

  • Q3 R&D fell to $70.1M from $86.3M, while SG&A rose to $57.6M from $24.3M, reflecting lower late-stage study costs and commercial launch investment.

Outlook and guidance

  • Elegrobart BLA submission for TED remains on track for Q1 2027; planned delivery, if approved, is via an at-home autoinjector with subcutaneous Q4W or Q8W dosing.

  • VRDN-008 Phase 1 data and FcRn portfolio development plans are expected in Q4 2026; VRDN-292 Phase 1 initiation in Graves’ disease patients is also planned for Q4.

  • Existing cash and anticipated Lumvoa revenue, plus potential elegrobart revenue if approved, are expected to fund current plans through profitability; September 30 liquidity was $955.2M.

  • Broad Lumvoa payer coverage remains a target within six to nine months of launch; a permanent J-code takes effect January 1, 2027.

  • A veligrotug MAA was submitted to the EMA in January 2026; review and approval timing remains subject to regulatory uncertainty.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Viridian Therapeutics earnings date

Logotype for Viridian Therapeutics Inc
Study update9 Nov, 2026
Viridian Therapeutics
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Viridian Therapeutics earnings date

Logotype for Viridian Therapeutics Inc
Study update9 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

Viridian Therapeutics Inc. is a biotechnology company focused on developing treatments for patients with serious diseases, particularly those related to rare and underserved conditions. The company’s primary area of research includes therapies for thyroid eye disease (TED) and other autoimmune and inflammatory diseases. Viridian Therapeutics employs innovative biologics and small-molecule technologies to address unmet medical needs and improve patient outcomes through targeted therapeutic approaches. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.